A smarter way for employers to offer GLP-1 access—with built-in cost control

GLP-1 (glucagon-like peptide-1 receptor agonists) medications have become one of the most talked-about, and most challenging, topics in employer-sponsored health plans.

What began as a treatment for diabetes is now widely used for weight management, driving unprecedented demand from employees. For employers, especially those with self-funded plans, this surge has created a difficult reality: GLP-1s are expensive, utilization is hard to predict, and traditional benefit funding models weren’t designed to absorb open-ended drug costs.

Eliminating coverage entirely is rarely a realistic option for competitive employers. Employees increasingly expect and rely on this access, making a supportive benefits package essential for attracting and retaining top talent.

So how can employers offer GLP-1 access with predictable costs?

Why GLP-1s break the traditional benefits model

GLP-1 medications don’t behave like most pharmacy benefits.

• Costs can exceed $1,000 per member per month
  
• Utilization varies widely across populations
  
• Long-term treatment plans vary person-to-person, driving complexity in cost-projections
  
• Spend is directly embedded into premiums and future renewals
  

As of December 2025, GLP-1s now account for more than 7% of all prescriptions, accelerating the problem. When GLP-1s are embedded in the medical or pharmacy plan, employers are exposed to utilization-driven cost increases with little ability to intervene.

This puts HR and benefits leaders in a tough position—balancing employee expectations against budget certainty and long-term sustainability.

The tradeoffs employers are being forced to make

Today, many employers feel boxed into a difficult choice that pits employee access against budget uncertainty. They are being forced to take sides: what’s best for the employees versus what’s realistic with today’s benefits cost and budgeting. This leaves them with few options, none of which fully align with managing risk and supporting employees:

1. Cover GLP-1s fully and absorb unpredictable, escalating costs that create significant strain on budget forecasts.
   
2. Eliminate coverage and shift costs to employees through funding mechanisms like HSAs or FSAs, risking employee dissatisfaction, trust erosion, and affordability issues without solving for the employer’s long-term financial exposure.
   

Many employers are forced into a decision by their health plan, which may suddenly cease coverage of GLP-1s and compel the employers to switch providers or find an alternative solution.

Bringing structure to GLP-1 coverage with a defined approach

An emerging strategy among employers is to carve GLP-1s out of the core medical plan and offer access through a defined, employer-funded health reimbursement arrangement (HRA).

Instead of open-ended coverage, employers establish clear parameters around how GLP-1 benefits are funded and administered.

This approach allows employers to:

• Define eligibility for GLP-1 reimbursement
  
• Set a monthly or quarterly funding amount
  
• Establish reimbursement rules aligned with plan goals
  
• Pay only for what is actually used, without upfront funding
  

The result is a benefit that offers access while restoring employer control.

Why a defined GLP-1 HRA model works

Predictable spend through defined contributions

A defined HRA replaces utilization-driven exposure with a fixed, budgetable contribution. Finance teams can model costs, HR can plan with confidence, and employers avoid surprise premium impacts tied to GLP-1 usage.

Access without embedding risk in the medical plan

Employees still have access to GLP-1 medications, but costs are no longer embedded in medical or pharmacy premiums. This reduces the risk that GLP-1 utilization drives future rate increases.

Better alignment with employer responsibilities

Unlike HSA-only approaches that shift responsibility to employees, HRAs are designed for employer governance, compliance, and cost containment. Employers maintain control over funding, eligibility, and benefit design.

What this means for employees

From an employee perspective, a defined GLP-1 HRA can still deliver meaningful value:

• Continued access to GLP-1 medications
  
• Choice in where and how prescriptions are filled
  
• A clear, employer-sponsored reimbursement experience
  
• Support while reducing out-of-pocket costs
  

When designed thoughtfully, this approach can preserve access while setting realistic boundaries.

What employers should look for in a GLP-1 HRA strategy

For this defined HRA approach to work, employers must prioritize factors that deliver both fiscal certainty and a clear, supportive experience for their employees. The strategic elements fall into two critical categories:

Employer priorities (cost control and governance)

• Predictable, capped funding: Establishing clear, defensible funding limits that finance teams can reliably model, moving GLP-1 costs from an unpredictable liability to a fixed, budgetable contribution.
• Clear compliance and governance: Ensuring the design has built-in controls for compliance, eligibility standards, and cost containment.
• Administrative flexibility: A solution that minimizes disruption to existing medical and pharmacy plans and is flexible enough to implement outside the typical annual renewal cycle.

Consumer priorities (access and experience)

• Continued access: The plan’s design must preserve employee access to GLP-1 medications while setting realistic, sustainable boundaries.
• Clear, simple reimbursement: Utilizing a “reimbursement-first” design that is straightforward and easy for employees to understand, reducing confusion and maximizing proper utilization.
• Transparent communication: A strategic employee communication plan is vital to maintain trust, ensure transparency, and clearly educate employees on eligibility and the reimbursement process.

The goal isn’t novelty. It’s sustainability.

The information in this blog post is for educational purposes only. It is not legal or tax advice. For legal or tax advice, you should consult your own counsel.

Copyright ©2026 WEX Inc. All rights reserved. The information in this document is subject to change without notice.